As The Pursuit For Allergan Inc. Continues, Valeant Pharmaceuticals International Hunts For More Deals—Including Contact Lenses

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO) on Thursday said it remains on the hunt for other companies, including makers of innovative contact lenses, as it presses on with efforts to take over Botox-maker Allergan Inc (AGN.N).

On a conference call with investors, Valeant Chief Executive Officer Michael Pearson said the company will not be content to remain the No. 4 global player in the contact lens industry.

Valeant officials said Allergan shareholders would profit more through a merger with Toronto-based Valeant than remaining a standalone company.

Help employers find you! Check out all the jobs and post your resume.

Back to news